Esteban Rodrigo Imedio

机构：Debiopharm (Switzerland) · ORCID：0000-0001-5666-666X

发表论文 41 篇 · 总被引 330 次 · h-index 11

代表论文

421 A first-in-human (FIH) phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT (2021 · Regular and Young Investigator Award Abstracts · 被引 36)
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors (2023 · Targeted Oncology · 被引 35)
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors (2023 · Investigational New Drugs · 被引 30)
Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors. (2019 · Journal of Clinical Oncology · 被引 29)
391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors (2020 · Regular and Young Investigator Award Abstracts · 被引 25)
Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation (2019 · Cancer Research · 被引 25)